|
Esophageal Neoplasms
|
0.600 |
CausalMutation
|
group |
CGI |
|
|
|
|
Esophageal Neoplasms
|
0.600 |
AlteredExpression
|
group |
BEFREE |
Thus, changes in gene copy number or level of expression of HER-I or c-myc DNA sequences may play an important role in the pathogenesis of esophageal cancer in this high-risk region.
|
2459070 |
1988 |
|
Esophageal Neoplasms
|
0.600 |
Biomarker
|
group |
BEFREE |
The int-2 and erbB genes are amplified more frequently than any other genes in human esophageal cancer.
|
9316622 |
1997 |
|
Esophageal Neoplasms
|
0.600 |
AlteredExpression
|
group |
BEFREE |
Northern blot analysis revealed a fourfold increase (p < 0.01) in EGF-R mRNA levels in the esophageal cancer samples in comparison with normal tissue samples.
|
10512940 |
1999 |
|
Esophageal Neoplasms
|
0.600 |
GeneticVariation
|
group |
BEFREE |
These data suggest that EGF-R and p53 mutation may be used as both outcome predictors and targets for molecular therapy for esophageal cancer.
|
14695149 |
2003 |
|
Esophageal Neoplasms
|
0.600 |
Biomarker
|
group |
BEFREE |
We review six aspects of the research literature on esophageal cancer: epidemiology and etiology, epidermal growth factor receptor and related growth factor receptors, cell cycle regulatory proteins, transforming growth factor-beta/Smad proteins, mismatch repair genes, and other genes.
|
15622457 |
2005 |
|
Esophageal Neoplasms
|
0.600 |
Biomarker
|
group |
BEFREE |
The selection of esophageal cancer patients for future studies with EGFR-TKIs based on the level of EGFR expression in their tumors or SCC histology should be considered.
|
16575012 |
2006 |
|
Esophageal Neoplasms
|
0.600 |
GeneticVariation
|
group |
BEFREE |
While more primary esophageal tumors remain to be screened for the mutations at the tyrosine kinase domain of EGFR, current observation implies that gefitinib may be worth further investigation for treatment of esophageal cancers.
|
16357520 |
2006 |
|
Esophageal Neoplasms
|
0.600 |
GeneticVariation
|
group |
BEFREE |
EGFR mutations in esophageal carcinoma are rare but do exist, and thus gefitinib could be included in esophageal cancer treatment regimens by selecting those patients who possess such mutations.
|
17142003 |
2007 |
|
Esophageal Neoplasms
|
0.600 |
GeneticVariation
|
group |
LHGDN |
EGFR mutations in esophageal carcinoma are rare but do exist, and thus gefitinib could be included in esophageal cancer treatment regimens by selecting those patients who possess such mutations.
|
17142003 |
2007 |
|
Esophageal Neoplasms
|
0.600 |
GeneticVariation
|
group |
LHGDN |
Influence of apoptosis (BCL2, FAS), cell cycle (CCND1) and growth factor (EGF, EGFR) genetic polymorphisms on survival outcome: an exploratory study in squamous cell esophageal cancer.
|
17912028 |
2007 |
|
Esophageal Neoplasms
|
0.600 |
GeneticVariation
|
group |
BEFREE |
Gene-gene interaction of EGFR 497Arg>Lys and EGF +61A>G polymorphisms enhanced risk for EC, indicating additive effects.
|
18773861 |
2008 |
|
Esophageal Neoplasms
|
0.600 |
GeneticVariation
|
group |
LHGDN |
Gene-gene interaction of EGFR 497Arg>Lys and EGF +61A>G polymorphisms enhanced risk for EC, indicating additive effects.
|
18773861 |
2008 |
|
Esophageal Neoplasms
|
0.600 |
Biomarker
|
group |
BEFREE |
Lapatinib inhibits receptor phosphorylation and cell growth and enhances antibody-dependent cellular cytotoxicity of EGFR- and HER2-overexpressing esophageal cancer cell lines.
|
21207425 |
2011 |
|
Esophageal Neoplasms
|
0.600 |
GeneticVariation
|
group |
BEFREE |
The EGFR CA repeat genetic polymorphism may act as a valuable molecular predictor of clinical outcome of esophageal cancer after CCRT and esophagectomy, especially in those with good response to CCRT.
|
21298351 |
2011 |
|
Esophageal Neoplasms
|
0.600 |
Biomarker
|
group |
CTD_human |
Targeting the human EGFR family in esophagogastric cancer.
|
21468131 |
2011 |
|
Esophageal Neoplasms
|
0.600 |
Biomarker
|
group |
CTD_human |
MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib.
|
22042947 |
2011 |
|
Esophageal Neoplasms
|
0.600 |
Biomarker
|
group |
CTD_human |
The EGFR CA repeat genetic polymorphism may act as a valuable molecular predictor of clinical outcome of esophageal cancer after CCRT and esophagectomy, especially in those with good response to CCRT.
|
21298351 |
2011 |
|
Esophageal Neoplasms
|
0.600 |
Biomarker
|
group |
BEFREE |
We evaluated the antitumor effects of lapatinib, a dual tyrosine kinase inhibitor which simultaneously inhibits EGFR and HER2, 5-fluorouracil (5-Fu) alone and in combination on esophageal cancer cells.
|
22293713 |
2012 |
|
Esophageal Neoplasms
|
0.600 |
AlteredExpression
|
group |
BEFREE |
Over-expression of epidermal growth factor receptor in esophageal cancer is associated with poor prognosis.
|
22555809 |
2012 |
|
Esophageal Neoplasms
|
0.600 |
AlteredExpression
|
group |
BEFREE |
In this report, the effect of PYM on EGFR expression in human esophageal cancer cells and the therapeutic efficacy of the combination of PYM and cetuximab on esophageal cancer xenograft were investigated.
|
22311160 |
2012 |
|
Esophageal Neoplasms
|
0.600 |
AlteredExpression
|
group |
BEFREE |
We report the outcome in a series of esophageal cancer patients treated at our center and the results of a retrospective analysis of epidermal growth factor receptor (EGFR) expression and EGFR/HER2 gene copy numbers taken as possible prognostic and predictive factors.
|
23052161 |
2012 |
|
Esophageal Neoplasms
|
0.600 |
Biomarker
|
group |
BEFREE |
More than 50% EGFR-positive EsC and MPM cells were resistant to EGFR-TKI, and susceptibility to EGFR-TKI growth-inhibitory effect correlated positively with expression of E-cadherin (epithelial gene marker) and negatively with mesenchymal gene markers.
|
23749888 |
2013 |
|
Esophageal Neoplasms
|
0.600 |
Biomarker
|
group |
BEFREE |
Epidermal growth factor receptor (EGFR), found in the epithelium of the digestive tract, plays an important role in epithelial repair and shows increased expression in different neoplasms, including esophageal tumors.
|
22875307 |
2013 |
|
Esophageal Neoplasms
|
0.600 |
GeneticVariation
|
group |
BEFREE |
EGFR intron-1 CA repeat polymorphism is a predictor of relapse and survival in complete resected only surgically treated esophageal cancer.
|
23377570 |
2014 |